INDUSTRIAL IMPACT

McMaster, Sartorius Stedim Biotech team up to advance biomanufacturing processes with next-gen tech

Sartorius Stedim Biotech S.A | August 23, 2021

Sartorius Stedim Biotech, a leading international partner of the biopharmaceutical industry, has entered into a partnership with McMaster University to improve manufacturing processes of antibody and virus-based treatments for diseases such as COVID-19, cancers, and genetic disorders.

Using a state-of-the-art multi-column chromatography system provided by Sartorius Stedim Biotech, the McMaster team will "perfect" a process for the purification of therapeutic viruses that is more effective and cheaper than those currently available. This will pave the way for new and more affordable treatments to reach patients with a variety of needs. "Teaming up with Sartorius Stedim Biotech is an exciting opportunity for McMaster Engineering. This research will push the envelope in leading advanced, cutting-edge research in bio-manufacturing," says John Preston, associate dean, research, innovation and external relations in the Faculty of Engineering. "Establishing industry-friendly, collaborative environments is critical in solving real-world problems."

This work aims to support the Sustainable Development Goals (SDG) set out by the United Nations, designed to give our people and planet a better future. More effective bio-manufacturing can make advanced biotherapeutics cost-effective and available to more people globally. "This partnership with McMaster University will lead to impactful research that will make important treatments available at a greater scale. We see this as a way to expand our research development and bring SDG-aligned pharmaceuticals to Canadian and global markets," says Brandon Corbett, research scientist at Sartorius Stedim Biotech.

David Latulippe, associate professor of Chemical Engineering, and Prashant Mhaskar, professor of Chemical Engineering and Canada Research Chair in Nonlinear and Fault-Tolerant Control, are leading this project with Sartorius Stedim Biotech. The collaboration will initially run for four years.

What is chromatography?

Chromatography is an essential purification technology in biomanufacturing. To produce biotherapeutics, scientists use a bioreactor with specialized cell lines and customized growth media. Next, the biotherapeutic must go through a series of purification steps, often with duplicate steps to satisfy the requirements of regulatory bodies.

Sartorius Stedim Biotechs' multi-column chromatography system uses parallel processing strategies to make the process more resource and cost-efficient. "Our ultimate goal is to perfect the downstream chromatography process by combining detailed experimental work with advanced process modelling concepts," says Latulippe. "This way, we can control the outcome and fix the processes on site, as production is happening, so everything is always 'on spec'." Currently, monoclonal antibodies are the leading biotherapeutic being used to fight against COVID-19.

Training the next generation

As part of the partnership, Sartorius Stedim Biotech will provide student training opportunities at their research and development facilities in North America and Europe. Ian Gough, a graduate of McMaster's Chemical and Bioengineering program, has already started working on this project. Gough is a former member of the Summer Studentship Internship program from BioCanRx, a Networks of Centres of Excellence program. Claire Velikonja, a recent chemical engineering graduate from the University of Toronto, will join the team in September.

Both Gough and Velikonja received a Canada Graduate Scholarship from Natural Sciences and Engineering Research Council of Canada (NSERC) to provide additional support for their first year of graduate studies.

A profile of Sartorius Stedim Biotech
Sartorius Stedim Biotech is a leading international partner of the biopharmaceutical industry. As a total solutions provider, the company helps its customers to manufacture biotech medications safely, rapidly and economically. Headquartered in Aubagne, France, Sartorius Stedim Biotech is quoted on the Eurolist of Euronext Paris. With its own manufacturing and R&D sites in Europe, North America and Asia and an international network of sales companies, Sartorius Stedim Biotech has a global reach. The Group has been annually growing by double digits on average and has been regularly expanding its portfolio by acquisitions of complementary technologies. In 2020, the company employed more than 7,500 people, and earned sales revenue of 1,910 million euros.

About McMaster University
Ranked among the world's top engineering schools, the Faculty of Engineering plays a significant role in helping McMaster University earn its reputation as one of Canada's most innovative universities. Our focus is on experiential, problem-based learning, and our interdisciplinary approach to collaboration results in smarter insights, groundbreaking ideas, and greater optimism. This approach is helping us create a Brighter World.

Spotlight

Look back at an exciting year of biotechnology innovations in Europe with the EuropaBio Annual Report 2018 - 2019.

Spotlight

Look back at an exciting year of biotechnology innovations in Europe with the EuropaBio Annual Report 2018 - 2019.

Related News

INDUSTRIAL IMPACT

eTheRNA Announces Research Agreement with Merck KGaA, Darmstadt, Germany to access mRNA technologies

eTheRNA | February 04, 2022

eTheRNA immunotherapies NV ("eTheRNA") is pleased to announce the start of a strategic partnership with Merck KGaA, Darmstadt, Germany with the signing of a Research Agreement. The partnership will investigate the application of eTheRNA's proprietary mRNA design expertise and LNP-delivery platforms to disease areas selected by Merck KGaA, Darmstadt, Germany. The ongoing pandemic has underlined the capability for mRNA vaccines as a new therapeutic modality. eTheRNA and Merck KGaA, Darmstadt, Germany both recognise the potential for using targeted mRNA therapeutics in an expanded range of diseases. With this collaboration, eTheRNA and Merck KGaA, Darmstadt, Germany will assess the feasibility of using eTheRNA's mRNA and LNP technologies to develop therapeutic vaccination approaches in models of disease. If successful, mRNAs encoding antigens nominated by Merck KGaA, Darmstadt, Germany and directly relevant for human diseases will then be designed and evaluated preclinically. "We are extremely pleased to sign this partnership agreement with Merck KGaA, Darmstadt, Germany, a leading German science and technology company. As two companies committed to innovation and creating patient focused solutions, we are excited about the many advantages such a partnership can offer to improve patient care and address a significant market need". Steven Powell, eTheRNA CEO About eTheRNA immunotherapies eTheRNA immunotherapies NV is developing immunotherapy and vaccine products for the treatment of cancer and infectious disease from its mRNA chemistry, antigen identification, lipid chemistry and delivery and process engineering platforms. The company is headquartered in Belgium and was established in 2013. Its founding shareholders include Progress Pharma and VUB. eTheRNA is supported by an international group of specialised investors; BNP Fortis Private Equity, Boehringer Ingelheim Venture Funds, Everjoy Fortune PTE. LTD, Grand Decade Development Limited, Fund+, LSP, Novalis Lifesciences, Omega Funds, PMV and Ying Zhou Enterprise Management Company Limited who share the Company's ambition to build a world-leading company in the RNA field. To date, the Company has raised €63 million of venture funding.

Read More

CELL AND GENE THERAPY

Gritstone bio and CEPI Expand Vaccine Agreement to Tackle Omicron Variant

Gritstone bio | December 07, 2021

Gritstone bio, Inc. a clinical-stage biotechnology company developing next generation cancer and infectious disease immunotherapies, and CEPI, the Coalition for Epidemic Preparedness Innovations, announced the expansion of their agreement in order to support the development of a self-amplifying mRNA vaccine designed to tackle the Omicron COVID-19 variant. CEPI will provide up to $5 million in additional funding to conduct a Phase 1 clinical trial of Gritstone’s Omicron vaccine candidate in South Africa, where a CEPI-funded clinical trial of Gritstone’s Beta variant COVID-19 vaccine is due to begin shortly. The SARS-CoV-2 T cell epitopes administered within Gritstone’s SAM COVID-19 vaccines are minimally impacted by mutations found within the Omicron variant, reinforcing the platform’s potential to address both Omicron and future variants of concern. CEPI is already funding up to $20.6 million to support preclinical studies, manufacturing process optimization, and a Phase 1 trial of Gritstone’s Beta variant vaccine candidate which will be initiated by South Africa’s University of the Witwatersrand in the coming weeks. The funding announced today will expand the Phase 1 trial to include additional arms to evaluate an Omicron-specific version of the vaccine. Gritstone has commenced manufacturing its SAM vaccine to specifically target the Omicron variant, and the Omicron arms of the Phase 1 trial are expected to begin in Q2 2022, subject to regulatory approval. The recently described Omicron variant, first identified in South Africa on November 9, 2021, was designated a variant of concern by the World Health Organization (WHO) on November 26, 2021. Early evidence suggests that Omicron carries an increased risk of re-infection, and sequence analysis has revealed many mutations in Spike, which may reduce clinical effectiveness of existing vaccines and/or therapeutic antibodies. Enabling equitable access CEPI is committed to global equitable access to COVID-19 vaccines so, through this agreement, CEPI and Gritstone have agreed that this Omicron vaccine candidate will be made available to the COVAX Facility for procurement and allocation, if it is proven to be safe and effective. The COVAX Facility aims to deliver equitable access to COVID-19 vaccines for all countries, at all levels of development, that wish to participate. “While key questions are yet to be answered about Omicron, its transmissibility, and its potential ability to evade our current vaccines, the stakes are too high to delay developing Omicron-specific vaccine candidates. Given the uncertainties, we must accelerate crucial R&D so vaccines are available to tackle Omicron as soon as possible – just in case we need them. There is no time to lose, so I’m pleased that within 10 days of Omicron being declared a Variant of Concern by the WHO, CEPI is expanding its partnership with Gritstone to support a new Omicron vaccine candidate which can be made globally accessible through COVAX.” Dr Richard Hatchett, CEO of CEPI “Our vaccine platforms are built on the premise that a best-in-class vaccine against a virus will drive strong neutralizing antibodies directed to surface antigens such as Spike, and strong cytotoxic T cell responses against other conserved viral antigens to eliminate virally infected cells. This broad immune response would, in principle, provide superior protection against a virus that is mutating its surface protein. Omicron is an example of a novel SARS-CoV-2 variant that may escape clinical protection conferred by vaccines that only afford narrow, Spike-specific immunity,” said Andrew Allen, M.D., Ph.D., co-founder, president and chief executive officer of Gritstone. “Our SAM technology provides an innovative platform likely capable of delivering on the attractive concept of broad, durable immunity. We are thrilled to be quickly expanding our relationship with CEPI in our shared goal of finding new vaccine solutions to battle this deadly virus on a global scale and help prevent current and perhaps future COVID outbreaks.” Self-amplifying mRNA vaccines As with the mRNA-based COVID-19 vaccines that are now in global use, self-amplifying mRNA vaccines use the body’s own machinery to make antigenic protein itself rather than injecting the antigen directly into the body. However, in self-amplifying mRNA vaccines, viral RNA is adapted in a way that allows only the genetic sequence for a specific antigen to be expressed, while keeping the part of the RNA that allows it to produce multiple copies of itself—the self-amplification machinery. The benefit of this approach is that the dose of RNA can be reduced while maintaining the potency of the vaccine. Gritstone’s vaccine candidate may also elicit T-cell immune responses against non-Spike gene fragments, which are slower to mutate than the genes associated with the SARS-CoV-2 Spike protein and could potentially provide broad protection against other SARS-CoV-2 strains. About CEPI CEPI is an innovative partnership between public, private, philanthropic, and civil organisations, launched at Davos in 2017, to develop vaccines against future epidemics. Prior to COVID-19 CEPI’s work focused on developing vaccines against Ebola virus, Lassa virus, Middle East Respiratory Syndrome coronavirus, Nipah virus, Rift Valley Fever virus and Chikungunya virus – it has over 20 vaccine candidates against these pathogens in development. CEPI has also invested in new platform technologies for rapid vaccine development against unknown pathogens. During the current pandemic, CEPI initiated multiple programmes to develop vaccines against SARS-CoV-2 and its variants with a focus on speed, scale and access. These programmes leverage the rapid response platforms developed by CEPI’s partners prior to the emergence of COVID-19 as well as new collaborations. The aim is to advance clinical development of a diverse portfolio of safe and effective COVID-19 candidates and to enable fair allocation to these vaccines worldwide through COVAX. CEPI’s 5-year plan lays out a $3.5 billion roadmap to compress vaccine development timelines to 100 days, develop a universal vaccine against COVID-19 and other Betacoronaviruses, and create a “library” of vaccine candidates for use against known and unknown pathogens. About the CORAL Program Gritstone’s CORAL program is a second-generation SARS-CoV-2 vaccine platform delivering spike and additional SARS-CoV-2 T cell epitopes, offering the potential for more durable protection and broader immunity against SARS-CoV-2 variants. Delivery vectors can comprise a chimpanzee adenovirus, self-amplifying mRNA or both (mix and match). The program is supported by several key relationships: Bill & Melinda Gates Foundation, National Institute of Allergy and Infectious Disease (NIAID), and the Coalition for Epidemic Preparedness Innovations (CEPI). An ongoing Gritstone-sponsored Phase 1 trial is evaluating SAM as a boost and immunogenicity enhancer of AstraZeneca's first-generation COVID-19 vaccine AZD1222 (Vaxzevria) in healthy adults ≥ 60 years in the UK. A two-dose SAM regimen is also being evaluated in an ongoing clinical trial sponsored by the National Institute of Health (NIH) Division of Microbiology and Infectious Disease and in the Coalition for Epidemic Preparedness Innovations-funded, Gritstone-sponsored clinical trial in South Africa expected to begin by year end 2021. About Gritstone Gritstone bio, Inc. a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases. Gritstone develops its products by leveraging two key pillars—first, a proprietary machine learning-based platform, Gritstone EDGETM, which is designed to predict antigens that are presented on the surface of cells, such as tumor or virally-infected cells, that can be seen by the immune system; and, second, the ability to develop and manufacture potent immunotherapies utilizing these antigens to potentially drive the patient’s immune system to specifically attack and destroy disease-causing cells. The company’s lead oncology programs include an individualized neoantigen-based immunotherapy, GRANITE, and an “off-the-shelf” shared neoantigen-based immunotherapy, SLATE, which are being evaluated in clinical studies. Within its infectious disease pipeline, Gritstone is advancing CORAL, a COVID-19 program to develop a second-generation vaccine, with support from departments within the National Institutes of Health (NIH), the Bill & Melinda Gates Foundation, the Coalition for Epidemic Preparedness Innovations (CEPI) and through a license agreement with La Jolla Institute for Immunology (LJI). Additionally, the company has a global collaboration for the development of a therapeutic HIV vaccine with Gilead Sciences. About COVAX COVAX, the vaccines pillar of the Access to COVID-19 Tools Accelerator, is co-convened by CEPI, Gavi, the Vaccine Alliance Gavi) and the World Health Organization – working in partnership with UNICEF as key implementing partner, developed and developing country vaccine manufacturers, the World Bank, and others. It is the only global initiative that is working with governments and manufacturers to ensure COVID-19 vaccines are available worldwide to both higher-income and lower-income countries.

Read More

MEDTECH

Avantor® will Increase Global Production of Single-Use Technologies to Meet the Biopharma Demand

Avantor | April 27, 2021

Avantor Inc., a main worldwide supplier of crucial items and administrations to clients in the existing sciences, trend-setting innovations, and applied materials businesses, today declared that it will increment worldwide limit with regards to top-notch single-use advances utilized in the creation of biologics and antibodies. In the U.S. what's more, in Europe, the Company will build its single-use producing impression by 30% and twofold its cleanroom space. The speculation will uphold developing client interest for monoclonal antibodies (mAbs), novel cell and quality treatments for oncology and different illnesses, just as immunizations, including those for COVID-19. Avantor as of late extended its Morrisville, North Carolina, single-use office and expects finish of a cleanroom extension at its Devens, Massachusetts, activity by mid-year. The Company likewise hopes to open its subsequent European single-use office in Hillegom, the Netherlands, by then too. Dr. Ger Brophy, Executive Vice President of Biopharma Production at Avantor, said, "The business' reaction to the COVID-19 pandemic has depended intensely on the incorporation of single-use items into biopharma creation measures. Adequacy and security are critical to our clients, and they look to us to comprehend and uphold their prerequisites as they quickly extend their assembling limit. "These options to our worldwide single-use fabricating biological system are basic strides in empowering our clients to get treatments to patients rapidly," Brophy added. The speculation further fortifies the Company's single-use organization, giving item consistency and abilities near bioproduction clients to help guarantee productive and continuous stock. About Avantor Avantor®, a Fortune 500 organization, is a main worldwide supplier of strategic items and administrations to clients in biopharma, medical care, training and government, and trendsetting innovations and applied materials enterprises. Our portfolio is utilized in essentially every phase of the main examination, advancement, and creation exercises in the enterprises we serve. Our worldwide impression empowers us to serve more than 225,000 client areas and gives us broad admittance to explore research facilities and researchers over 180 nations. We set science underway to make a superior world.

Read More